Loading…
4D Molecular Therapeutics, Inc. is projected to rise to $14.09 by 2027, a +14% move from its current price of $12.31. FDMT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $11.83 | $12.32 | $12.83 | +0.07% |
| Jul 14 | $11.63 | $12.33 | $13.06 | +0.13% |
| Jul 15 | $11.49 | $12.33 | $13.24 | +0.20% |
| Jul 16 | $11.37 | $12.34 | $13.39 | +0.26% |
| Jul 17 | $11.27 | $12.35 | $13.53 | +0.33% |
| Jul 18 | $11.18 | $12.36 | $13.66 | +0.40% |
| Jul 19 | $11.10 | $12.37 | $13.78 | +0.46% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.10 | $12.37 | $13.78 | +0.46% |
| Week 2 | $10.66 | $12.42 | $14.47 | +0.92% |
| Week 3 | $10.35 | $12.48 | $15.05 | +1.39% |
| Week 4 | $10.10 | $12.54 | $15.56 | +1.86% |
| Week 5 | $9.89 | $12.60 | $16.04 | +2.33% |
| Week 6 | $9.71 | $12.65 | $16.49 | +2.80% |
| Week 7 | $9.55 | $12.71 | $16.92 | +3.27% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
FDMT is the ticker for 4D Molecular Therapeutics, Inc. It is currently priced at $12.88 and has a market cap of $673.32M with a rank of 2694.
The long-term price outlook points to a rising trajectory, with 2026 averaging $12.88 and 2030 averaging $27.76, 2040 averaging $64.45, and 2050 averaging $161.76.
Forecasts also show higher potential prices in later years: 2026 max $18.64, 2030 max $46.81, 2040 max $135.61, and 2050 max $372.05, with a cumulative upside reflected by a 2050 ROI of 1155.9 (bullish sentiment).
A major floor 45.1% below — a decisive break under it would weaken the trend.
The nearest floor, 29.8% below — buyers have tended to step in here.
The nearest ceiling, 8.0% above — a clean break opens room to run.
A major ceiling 30.6% above — clearing it would confirm fresh momentum.
Key FDMT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of FDMT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $12.75 | Sell | $12.66 | Sell |
| MA 10 | $12.72 | Sell | $12.42 | Sell |
| MA 20 | $11.35 | Buy | $11.69 | Buy |
| MA 50 | $10.13 | Buy | $10.61 | Buy |
| MA 100 | $9.75 | Buy | $9.98 | Buy |
| MA 200 | $9.62 | Buy | $9.33 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.72 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 44.38 | Neutral |
| Williams %R (14) | -34.37 | Info |
| MACD (12,26,9) | 0.06 | Buy |
| ROC (12) | 6.12 | Buy |
| Bollinger %B (20,2) | 0.65 | Neutral |
| Stochastic %K (14) | 65.63 | Neutral |
| TRIX (15) | 1.22 | Buy |
| Awesome (5,34) | 2.33 | Buy |
| Ultimate (7,14,28) | 44.89 | Neutral |
| Momentum (10) | 0.79 | Buy |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 12.76 | Sell |
| ADX (14) | 25.77 | Buy |
| ATR (14) | 0.39 | Info |
The near-term technical picture is bullish with RSI14 at 70 and price action existing above key moving averages. The SMA50 is $9.64 and the SMA200 is $9.38, indicating near-term momentum.
FDMT traded within a 30-day range of $9.35 to $17.75, highlighting the current volatility and potential resistance near the upper end of that range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.19 | $12.31 | $17.46 | 0% | Neutral | |
| $10.70 | $14.09 | $19.90 | +14% | Neutral | |
| $10.15 | $13.97 | $20.77 | +13% | Neutral | |
| $13.74 | $19.61 | $30.36 | +59% | Bullish | |
| $16.94 | $25.01 | $40.01 | +103% | Bullish | |
| $17.62 | $26.82 | $44.16 | +118% | Bullish | |
| $19.69 | $30.84 | $52.10 | +151% | Bullish | |
| $18.62 | $29.97 | $51.81 | +143% | Bullish | |
| $19.01 | $31.41 | $55.46 | +155% | Bullish | |
| $21.32 | $36.13 | $65.05 | +194% | Bullish | |
| $29.55 | $56.41 | $110.08 | +358% | Bullish | |
| $62.53 | $138.96 | $304.18 | +10.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $7.19 | $12.31 | $14.93 | +0.00% |
| August 2026 | $10.84 | $12.97 | $16.05 | +5.33% |
| September 2026 | $10.81 | $13.07 | $16.44 | +0.80% |
| October 2026 | $10.43 | $12.72 | $16.22 | -2.66% |
| November 2026 | $10.59 | $13.02 | $16.79 | +2.35% |
| December 2026 | $10.82 | $13.40 | $17.46 | +2.90% |
Click any year to see its month-by-month FDMT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
4D Molecular Therapeutics, Inc.'s 2026 outlook centres on $12.31, within a $7.19 to $17.46 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, FDMT could reach as high as $19.90, with a base case around $14.09 and support toward $10.70 — roughly +14% from $12.31. A consolidation phase looks the most probable path here.
Expect FDMT to range from $10.15 to $20.77 through 2028. The $13.97 average target implies a +13% move from current prices. That is -1% versus the projected 2027 average. Price action looks broadly range-bound.
The FDMT price prediction for 2029 points to an average of $19.61 (low $13.74, high $30.36) — a potential gain of +59% on today's $12.31. Buyers look set to stay in control over this stretch.
In 2030, FDMT is projected to trade between $16.94 and $40.01, averaging $25.01 — a potential gain of +103% from today's $12.31. That is up +27% on the projected 2029 average. Momentum favours further upside here.
4D Molecular Therapeutics, Inc.'s 2031 outlook centres on $26.82, within a $17.62 to $44.16 range. That is up +7% on the projected 2030 average. That marks a +118% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, FDMT could reach as high as $52.10, with a base case around $30.84 and support toward $19.69 — roughly +151% from $12.31. Momentum favours further upside here.
Expect FDMT to range from $18.62 to $51.81 through 2033. The $29.97 average target implies a +143% move from current prices. That is -3% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The FDMT price prediction for 2034 points to an average of $31.41 (low $19.01, high $55.46) — a potential gain of +155% on today's $12.31. Momentum favours further upside here.
In 2035, FDMT is projected to trade between $21.32 and $65.05, averaging $36.13 — a potential gain of +194% from today's $12.31. That is up +15% on the projected 2034 average. Buyers look set to stay in control over this stretch.
4D Molecular Therapeutics, Inc.'s 2040 outlook centres on $56.41, within a $29.55 to $110.08 range. That is up +56% on the projected 2035 average. That marks a +358% change versus current levels. Momentum favours further upside here.
By 2050, FDMT could reach as high as $304.18, with a base case around $138.96 and support toward $62.53 — roughly +10.3x from $12.31. Buyers look set to stay in control over this stretch.
Investing $1,000 in FDMT today (≈ 81.234768 FDMT) could be worth
$11,288.41
+$10,288.41 (+1029%) by 2050 · US Dollar
Based on the average projected FDMT price of $138.96 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in FDMTwould be worth at today's price.
$1,000 invested in FDMT on Jul 10, 2025 (≈ 229.885063 FDMT) would be worth
$2,829.89
+$1,829.89 (+183.0%) today · 2.83× · US Dollar
Based on a FDMT entry price of $4.35 vs. today's $12.31.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $13 | $946.92 | -5.3% |
| 1 month ago | $8.72 | $1,411.7 | +41.2% |
| 3 months ago | $9.81 | $1,254.84 | +25.5% |
| 6 months ago | $7.5 | $1,641.33 | +64.1% |
| 1 year ago | $4.35 | $2,829.89 | +183.0% |
| All time (5.0y) ago | $22.73 | $541.58 | -45.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our FDMT forecast.
Our base-case forecast reaches $25.00 around 2030.
Implied market cap at $25.00: $1.31B
The multi-year forecast shows substantial upside, with 2029 averaging $21.40 and ROI 66.1, 2030 averaging $27.76 and ROI 115.5, 2040 averaging $64.45 and ROI 400.4, and 2050 averaging $161.76 with ROI 1155.9. The sentiment shifts to bullish from 2029 onward, suggesting a sustained positive outlook through 2030, 2040, and 2050.
Volatility remains a consideration, as the annualized volatility is 90%, underscoring the potential for larger price swings alongside the projected gains.
Tap a question to reveal the answer.
min $17.76, avg $27.76, max $46.81; ROI 115.5; sentiment BULLISH.
The forecast includes positive ROI values in multiple years (2027: 12, 2028: 15.1, 2029: 66.1, 2030: 115.5, 2050: 1155.9) and bullish sentiment for later years, though these are estimates and not guarantees.
Yes, the 2050 max is $372.05 and the 2050 avg is $161.76, with 2040 max $135.61 and 2029 max $34.75, indicating that reaching or exceeding $100 is possible according to the forecast.
Current price $12.88; Market cap $673.32M; Rank 2694.
Sentiment BULLISH; RSI14 70; SMA50 $9.64; SMA200 $9.38; 30-day range $9.35 to $17.75; support $8.36; resistance $12.88; annualized volatility 90%.
4D Molecular Therapeutics, Inc. Community Discussion
0Share your 4D Molecular Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.